Abstract
To the Editor:
Having been participants in the clinical trials of Fluosol-DA, 20 percent, we share some of the concerns of Gould et al. (June 26 issue)
1
and agree with their warning not to take these results out of context. Unfortunately, their conclusions reflect a tendency to do just that. This small number of "highly select" patients, studied without a control group, does not provide sufficient evidence that Fluosol-DA is an "inadequate red-cell substitute in acute anemia." Any study of only eight patients has little statistical power and therefore little chance of demonstrating a significant treatment effect. Before evaluating the . . .